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ABSTRACT
This article reviews the change in the reimbursement and pricing system
in South Korea, which was the precursor to the eventual implementation
of evidence-based decision-making. There has been pressure on Korea’s
National Health Insurance system to control its skyrocketing expendi-
tures on drugs. As a result, a series of cost-containment policies have
been implemented. The idea of economic evidence-based decision-
making was ﬁrst introduced in Korea in 2001 when the government
announced cost-effectiveness as one of the criteria for reimbursement
decisions. After this announcement, the Health Insurance Review and
Assessment Service (HIRA) developed guidelines, which became the stan-
dard for economic evaluations.
In 2006, the drug listing system for reimbursement was changed from
a negative to a positive system under the drug expenditure rationalization
plan. Under this new system, only drugs that are proven economically and
clinically valuable can be listed, and applicants have to submit economic
evaluation studies to support the cost-effectiveness of their drugs. Once
new applications are submitted, HIRA reviews them, and the Drug Reim-
bursement Evaluation Committee (DREC) decides whether or not to rec-
ommend the submitted drugs. In its reimbursement decisions, the DREC
considers not only cost-effectiveness but also the availability of therapeutic
alternatives, the severity of the condition treated, and the impact on the
budget, among other measures. After the introduction of the positive list
system, 56% of drugs were determined to be appropriate for reimburse-
ment by the DREC. Despite limited human resources, experience, and
quality local data, Korea is continuing to make efforts to establish a system
of evidence-based decision-making.
Keywords: drug reimbursement, economic evaluation, PE guidelines, posi-
tive list.
Background
According to Organization for Economic Co-operation and
Development (OECD) health data, the share of drug expendi-
tures from total Korean health expenditures was around 26% in
2006 [1]. This ﬁgure places South Korea as the fourth highest
among OECD countries and is the main reason why the control
of drug expenditures has surfaced as a social issue.
In 2000, South Korea initiated reforms that separated the role
of prescribing and dispensing. Nevertheless, contrary to expec-
tations, drug expenditures did not decrease despite the fact that
the use of certain drugs such as antibiotics and some injected
drugs fell. This is attributable to the fact that some drugs that
were previously purchased outside of the health insurance system
now require a prescription. In addition, physicians who used to
prescribe generic drugs in the past because of the higher margin
of those drugs switched to brand name drugs when the ﬁnancial
incentive was eliminated. As a result, pharmaceutical expendi-
ture per capita, which was actually US$158 in 1998, increased to
US$236 in 2001, which was a higher rate of increase than other
medical expenditures [1].
South Korea’s National Health Insurance system, which had
experienced deﬁcits for a considerable length of time, requested a
more fundamental change in drug reimbursement and pricing
policies [2]. This led to the introduction of a series of cost-
containment policies in late 2001. These policies included a
triennial price revision policy and drug use monitoring. A refer-
ence price system was also considered but was ultimately rejected
because of objections from industry, physicians, and patient
groups.
In addition to these policies, the government announced a
new regulation at the end of 2001, which, for the ﬁrst time,
introduced the idea of economic evidence-based decision-making
to South Korea. The new regulation states that decisions on the
reimbursement of newly submitted health technologies should
consider the economic aspects, that is, the cost-effectiveness
of the new technology. In accordance with this new regulation,
the Health Insurance Review and Assessment Service (HIRA)
decided to formulate a methodological standard of economic
evaluation and began to draft the South Korean version of the
pharmacoeconomic guidelines in 2003.
Nevertheless, despite many attempts at countering it, drug
expenditures continued to rise. In May of 2006, the government
announced the drug expenditure rationalization plan (DERP),
which focused on the introduction of a “positive list system
(PLS)” [3]. According to the announcement, companies that
wanted to list a new drug on the national formulary had to
submit an economic evaluation to verify its value. Only those
drugs acknowledged as valuable or necessary by the system could
be reimbursed at the price negotiated with The National Health
Insurance Corporations (NHIC). In addition to new drugs, cur-
rently listed drugs are also scheduled to be reevaluated over a
5-year period. Products that do not prove their clinical or eco-
nomic value are to be eliminated from the national formulary in
the future, even if they were already listed.
Although the pharmaceutical industry strongly opposed the
DERP, the South Korean people agreed to the principle that only
clinically and economically valuable drugs be listed, leading to
the announcement of the regulation at the end of December 2006
and to the initiation of the new system in 2007. The South
Korean policy stems from an environment that differs substan-
tially from those of other countries such as Australia, UK, and
Canada, where the listing system did not change when the gov-
ernment decided to use pharmacoeconomic (PE) data to support
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evidence-based decision-making. This article intends to review
how drug insurance policies have changed through the evidence-
based decision-making process. The focus will be given ﬁrst to
the development process and contents of South Korean pharma-
coeconomic guidelines and then to the detailed process and the
main issues surrounding the new PLS of South Korea.
Development Process and Contents of
HIRA Guidelines
Development Process
As mentioned earlier, HIRA began formulating the South Korean
version of the pharmacoeconomic guidelines in 2003 after the
announcement of the new regulations at the end of 2001.
The guideline development team at HIRA ﬁrst reviewed exist-
ing international guidelines, academic journals, and other related
literature. The main issues to be considered in establishing the
direction and scope of the guidelines were then screened. When
the main issues became clear, HIRA created an advisory commit-
tee consisting of prominent Korean scholars within the ﬁeld and
discussed those selected issues. Based on literature review and the
consensus of the expert group, it drafted its ﬁrst version of the
guidelines. Experts in epidemiology and statistics and key ﬁgures
in industry, along with the existing advisory committee members,
reviewed the contents of the ﬁrst draft. In addition, HIRA held an
open workshop in June of 2005, at which time the public could
comment on the guidelines [4]. The draft guidelines were revised
to reﬂect public comments and were presented to the Drug Reim-
bursement Evaluation Committee (DREC) for endorsement.
They were ofﬁcially published by HIRA in June of 2006.
In South Korea, stakeholders participated in the discussion
process in the later stage because there were few experts in the
industry in the period from 2003 to the beginning of 2004.
Because PE experts are active in the industry at present, however,
they will likely play a more prominent role in any future guide-
line revision processes.
When HIRA formulated the guidelines, many countries
around the world were already using their own pharmacoeco-
nomic guidelines, of which several were known internationally.
Because most of them were similar in content, we could have
adopted one of them rather than developing one of our own [5].
Nevertheless, HIRA formulated its own guidelines out of the
awareness that South Korea did not have enough research expe-
rience and that the quality local data available in South Korea
were not the same with those in other countries such as the UK,
Australia, and Canada. There was thus a need to formulate
guidelines that reﬂected the local situation. It was also taken into
consideration that discussions of methodological issues among
researchers could be facilitated through the guideline develop-
ment process and that the process could also contribute to the
establishment of an academic infrastructure.
Contents of Guidelines
The HIRA guidelines comprise two parts: guidance and explana-
tory notes. The full version of the HIRA guidelines is posted on
the HIRA Web site (http://www.hira.or.kr/). Nevertheless, only
the Korean-language version is available as of this writing.
Therefore, some of the important components are summarized
here in a comparison with other international guidelines [6].
The selection of a comparator. With regards to the selection of a
comparator, the HIRA guidelines demand that in cases in which
there are comparable drugs, the most prevalent drug should be
selected as a comparator. Comparable drugs are drugs that have
been used to treat or control a target disease or an indication of
the submitted drug, and that can be substituted for the submitted
drug. Nevertheless, comparable drugs are not limited to those
that have the same therapeutic mechanism. As for the unit cost of
the selected comparator, the price of the generic version should
be considered in cases where a generic version of a comparator
has been released. That is, the weighted average price of each
molecule should be reﬂected as the unit cost of the selected
comparator.
Data sources. A less biased data source for costs and effects,
such as a randomized controlled trial, is recommended. The use
of head-to-head trials that directly compare the proposed drug
with comparators is also strongly preferred. If a head-to-head
trial is not possible, however, an indirect comparison is accept-
able. The details of the data search procedure and the rationale
for the selection should be clearly described.
Analytic perspective. HIRA guidelines recommend that the
analysis should adopt a societal perspective. Therefore, all costs
that are appropriate, from a societal perspective, should be
included. Nevertheless, the guidelines have reserved opinions on
several items. It recommends that productivity costs not be
included in base case analysis but be presented separately or in a
sensitivity analysis. In addition, the future medical cost of any
unrelated disease is open for theoretical debate, but the guide-
lines recommend that it not be included in base case analysis to
secure comparability.
Final versus surrogate outcome. A ﬁnal intended outcome,
rather than a surrogate outcome, is recommended for the
outcome indicator because there is uncertainty in the relationship
between the surrogate and ﬁnal outcomes. Moreover, it is difﬁ-
cult to judge the economic implication of an increase of one unit
in a surrogate outcome.
Handling uncertainty. Uncertainty in the analysis should be
examined by executing a sensitivity analysis. The HIRA guide-
lines currently state that at least a one-way sensitivity analysis
should be executed for all uncertain variables, but presenting
results using a more advanced method such as probabilistic sen-
sitivity analysis is also encouraged.
Discount rate. Costs and outcomes should be discounted at 5%
per year. In addition, sensitivity analyses with 0%, 3%, and
7.5% should also be presented.
Adapting data from a different setting. If there is quality local
data for an evaluation, the use of such data is the best means of
reﬂecting the local situation. Nevertheless, this is not always
possible. When adapting data from a different setting, the HIRA
guidelines state that the price and medical utilization data must
be domestic, even though HIRA will permit citations from
foreign studies if they are related to clinical effects or disease
epidemiology. Of course, in the case that South Korea’s treatment
pattern for the disease is different from that of the country of
origin of that particular data, it is suggested that a sensitivity
analysis of the domestic situation be carried out. In the case of
multinational trials involving local participation, a sensitivity
analysis with speciﬁc domestic samples should accompany the
base case analysis.
Reporting results. The pharmacoeconomic evaluation report
should be described in such detail that interested readers can
follow the background and procedure of the evaluation and
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reviewers can replicate the entire analysis process. To enhance the
clarity and to facilitate communication among researchers and
reviewers of the pharmacoeconomic studies, the ﬁnal report
should be written using a structured format.
Prospects for Revision
A variety of issues have surfaced during the more than 3 years
since the announcement of the ﬁrst draft, and some have pointed
out the need for an update to the guidelines.
The most important issue regarding the guidelines is the
controversy related to the selection of comparators. The guide-
lines currently suggest that the most prevalent among compa-
rable drugs should be selected as the comparator. The problem is
that because the guidelines are not prescriptive enough, they
occasionally lead to cases in which the comparator selected by
the pharmaceutical companies and that considered appropriate
by HIRA are different. Therefore, companies demand more
transparent guidelines, but it is difﬁcult to set clear and detailed
criteria for the range of comparable drugs. For instance, some
drugs are used as substitutes for other drugs despite the fact that
the two drugs have different therapeutic mechanisms, whereas
some others cannot substitute for other drugs because of the
difference in the mechanism. HIRA is currently attempting to
approach this problem by initiating a prior-consultation system.
The next issue is the standard of indirect comparison. The
guidelines state that an indirect comparison is possible in cases
where there is no head-to-head trial with a comparator, but it
states nothing further on the subject. There are no guidelines for
the method of indirect comparison. Because the relative effective-
ness of comparative drugs has a large effect on cost-effectiveness,
more speciﬁc guidelines pertaining to indirect comparisons are
needed.
Lastly, the point has to be made that there is a gap between
the perspectives of the guidelines and the perspectives that appli-
cants are actually using. Most submitted economic evaluation
studies include only direct medical costs. HIRA has not raised
this issue because it is a more conservative approach. Neverthe-
less, if some studies are executed from a societal perspective and
some are executed from a narrower perspective, problems of
inconsistency can arise. Therefore, there is a need to review
whether the guidelines will maintain a societal perspective or
permit the use of a narrower perspective reﬂecting the actual
study perspectives of current submission documents.
Introduction of the PLS and Economic
Evaluation of New Drugs
Process of New Drug Listing under the PLS
With the introduction of the PLS in 2007, pharmacoeconomic
evaluations were formally used to answer policy questions
regarding drug reimbursement. Under the negative list system, all
drugs that were approved by the Korea Food and Drug Admin-
istration could automatically be listed for reimbursement, with
only a few exceptions [7]. Nevertheless, with the change from the
negative to the PLS in 2007, only clinically and economically
valuable drugs can be listed based on the presented evidence of
comparative cost-effectiveness.
Figure 1 shows the entire process of listing under the PLS.
Once a company submits the application documents for a drug,
in-house staff at HIRA reviews them. Health economists in the
research department and experts outside of HIRA are sometimes
invited for consultations for more professional and high-level
reviews. The DREC, composed of 18 members, has a mandate to
review submissions and make recommendations on listings [8].
After a period of deliberation, one of three reimbursement deci-
sions is made: positive recommendation, rejection, or restriction
by indication. The NHIC negotiates the price of drugs with a
positive recommendation with the manufacturer.
If an agreement cannot be reached through drug price nego-
tiations, patient treatment is guaranteed for necessary drugs
through compulsory listing by the Beneﬁt Coordination Commit-
tee (BCC), which can mediate and determine the price [8]. The
Ministry of Health, Welfare and Family Affairs has provided a
legal basis to secure the accessibility of necessary drugs. By law,
even if a pharmaceutical company does not apply for listing or if
price negotiations fail, drugs evaluated as being necessary for
treatment can be directly listed. For example, cancer drugs (dasa-
tinib, imatinib), and an anti-HIV agent (enfuvirtide) went through
the BCC after the failure of price negotiations. Nevertheless, it
remains up to pharmaceutical companies to determine whether
they will supply the drugs at the price mediated by the BCC.
A
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Figure 1 Process of the listing of a new drug in
South Korea. HIRA, Health Insurance Review and
Assessment Service; MOHW, Ministry of Health
and Welfare; NHIC, National Health Insurance
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In addition, to strengthen stakeholder involvement and trans-
parency, pharmaceutical companies are given the opportunity to
participate in the hearing process and to request a reevaluation.
The development of PE guidelines has incorporated consistency
and transparency throughout the review, and HIRA also prepares
checklists for reviewers to ensure the consistency of reviews by
minimizing variations between reviewers, which enhances the
transparency of the system. Once a detailed evaluation standard
for each case is determined through deliberation by the DREC,
they are posted on the HIRA Web site. HIRA has also imple-
mented conﬂict-of-interest guidelines. Committee members are
not expected to attend meetings where submissions in which they
have a conﬂict of interest are being considered.
PE Study Submission and Decision-Making
Table 1 shows the number of PE studies submitted to HIRA. In
2007, a total of 26 PE studies were submitted. Nevertheless,
there were 129 new drug applications, a fact that indicates that
many of the submitted drugs did not include PE data [9]. This
occurred because submitted drugs with lower prices relative to
that of an existing drug were exempt from providing PE data and
because companies chose a strategy of lowering the price instead
of submitting PE data if the products were not proven to be
effective to an extent that justiﬁed the price. Considering that PE
data submission became mandatory in 2008, it is puzzling that
the number of submissions in 2008 was lower than that of 2007,
although the 2008 submissions reﬂect only the ﬁrst half of the
year. It can be conjectured that companies only submit PE studies
when they are conﬁdent of cost-effectiveness. When they are not,
they choose a strategy of preparing for price negotiations at an
early stage instead of going through the complex and costly
process of ensuring a premium price.
Under the PLS, the DREC considers various factors for reim-
bursement decision making, including the cost-effectiveness, the
availability of therapeutic alternatives, the severity of the condi-
tion treated, clinical effectiveness, the budget impact after the
introduction of the drug, the listing conditions in other countries
and the uncertainty in the evidence presented. In order to evalu-
ate whether the cost-effectiveness of a submitted drug is accept-
able, the maximum willingness to pay for a QALY (Quality
Adjusted Life Year) can be an important reference. It, however,
has not yet been ofﬁcially designated in South Korea. The DREC
decision-making process results over the years show that per
capita GDP was referred to as a threshold for the incremental
cost-effectiveness ratio (ICER) in decision-making; nevertheless,
reimbursement decisions have been made with ﬂexibility by con-
sidering social values as well [10].
Regarding decisions made for reimbursement and pricing,
56.0% of items evaluated by the committee, comprising a total of
47 items, were determined as being appropriate for reimburse-
ment after the introduction of the PLS in 2007. Ten of these have
completed price negotiations. The reimbursement rate is lower
than that of the previous years, 62.0% in 2005 and 76.0% in
2006, respectively (Table 2).
Reevaluation of Listed Drugs
The South Korean government has announced that all listed
drugs will be reevaluated by the same standard of cost-
effectiveness under the PLS. In 2007, when the PLS was ﬁrst
introduced, nearly 20,000 drugs were already listed for insurance
under the negative list system; thus, a plan was set to reevaluate
the list over 5 years, by 2011 [3]. In the 1st year, a pilot project
on migraine and hyperlipidemia drugs was initiated.
As a result of the reevaluation, drugs that were not considered
to be cost-effective were eliminated from the list. Nevertheless,
drugs remained on the list if pharmaceutical companies accepted
the evaluation results and made voluntary price cuts. The pilot
project results show that out of 11 ingredients for migraine, 8
remained on the list, 2 lowered their prices, and 1 was listed with
restrictions [11]. Evaluations of hyperlipidemia drugs are still in
progress, but it is predicted that there will be up to a 30% price
cut.
Since the initiation of the pilot project, many issues related to
reevaluations of listed drugs have been raised. One signiﬁcant
issue is the debate about the purpose of the PLS. The results of
the reevaluations of migraine and hyperlipidemia drugs show
that drugs eliminated from the list are comparatively few and
that most remain on the list through price cuts. The debate
involves whether the results correspond with the basic purpose of
the PLS [12]. The second issue is whether the reevaluations can
be adequately and thoroughly completed by 2011. Listed drugs
have a great deal of supporting evidence, which requires a con-
siderable amount of manpower, time, and money to evaluate. At
this point, there is not yet a well-established solution to this
problem.
In the interim, there was also controversy regarding several
methodological issues, including the method of indirect compari-
son, the selection of an outcome indicator, and the precision of
medical costs calculated through claims data. In addition, the
fact that the assessment and appraisal processes are not clearly
separated and that decision-making is too dependent on the
Table 1 PE studies submitted to HIRA
Period
No. of
submissions
Submissions with PE studies
MNC Local Total
June 2005–December 2006 — — — 13
2007 129 20 6 26
2008 (~June 30) 58 3 2 5
Source: Health Insurance Review and Assessment Service, 2008.
HIRA, Health Insurance Review and Assessment Service; MNC, multi national countries.
Table 2 Decisions made for reimbursement and pricing in South Korea
Decision
2007 (Jan 2007~April 2008) 2006* 2005*
No. of drugs % No. of drugs % No. of drugs %
Reimbursement and pricing complete 10 11.9 79 76.0 31 62.0
Reimbursement complete but price negotiation in process 26 31.0 — — — —
Reimbursement complete but price negotiation fails 11 13.1 — — — —
Delisted (fail) 25 29.8 14 13.5 14 28.0
Request for reevaluation 12 14.3 11 10.6 5 10.0
Total 84 100.0 104 100.0 50 100.0
*There was no price negotiation process before 2007.
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assessment report reduces the likelihood of a thoughtful decision
based on various social values [13].
Major Barriers for Economic Evaluation
The limited availability of human resources with expertise is
one of the most important barriers in conducting economic
evaluations. Pharmacoeconomics education has made signiﬁ-
cant advances since the introduction of the PLS, but there
remains a lack of experts who can actually perform the studies.
Academia has gradually shown an interest in PE studies, but
there has not been enough accumulated knowledge and expe-
rience to go through the controversial issues. This situation has
arisen partly because for now, most research demands in aca-
demia are adaptation studies based on core models developed
by the headquarters of pharmaceutical companies, which are
under pressure to complete them in a short period of time. This
can be a limitation in capturing the attention of the academic
world. There are also some experts currently working at phar-
maceutical companies. Nevertheless, instead of directly con-
ducting pharmacoeconomic evaluations in-house, companies
prefer to outsource to universities or private consulting com-
panies. This actually limits their opportunities for pharmaco-
economic evaluation experience.
The lack of local data is another challenge. It is not always
possible to ﬁnd quality local clinical or epidemiological data. In
this regard, PE guidelines permit the use of international data to
acquire clinical efﬁcacy and disease progression-related esti-
mates. It requires local data only on the price and medical uti-
lization. Nevertheless, there are cases in which the incidence or
prevalence of a disease differs from that of other countries
(especially Western countries). This inﬂuences the absolute
beneﬁt of the drug. Furthermore, genetic differences and differ-
ences in medical practices affect the clinical beneﬁt. Therefore,
there is a need to establish patient registries and to promote the
use of the claims databases that are available in South Korea
[14].
There is yet limited social consensus on bridging the gap
between the ICER value for pharmacoeconomic studies and
decision-making. First, the fundamental problem is that no ofﬁ-
cial deﬁnition of an explicit ICER threshold for decision-making
in South Korea exists. Nevertheless, even if there were a thresh-
old, it would be difﬁcult to connect it directly to decision-making
because ﬁrst, there is uncertainty and limits in data sources and
study method, and second, there are many factors that are
considered in reimbursement decisions in addition to cost-
effectiveness. Unfortunately, there is no ﬁxed decision rule to
reﬂect the qualitative aspects of social values.
Therefore, there must be a more formative discussion regard-
ing the gaps that inevitably exist between pharmacoeconomic
evaluations and decision-making. It is currently necessary to
accumulate domestic decision-making experience and compre-
hensively reﬂect the various factors considered in decision-
making processes to generate a more detailed evaluation
standard. Such efforts will contribute to a soft landing of the PLS
by reducing the uncertainty in decision-making and improving
the degree of predictability.
Conclusion
South Korea is the ﬁrst Asian country to formulate PE guidelines
and require the submission of economic evidence when applying
for a listing for insurance. Nevertheless, the system has to operate
in a challenging environment in many ways compared with those
of other countries with established evaluation systems because it
lacks local data, experience in evidence-based decision-making,
and experts who can conduct pharmacoeconomic analysis. Occa-
sionally, there are conﬂicts in the process of executing policies
because of the lack of shared experience among the government,
stakeholders, and academia. Nevertheless, because the current
situation is not simply an addition of one standard, pharmaco-
economics, but is a fundamental change in the listing system
from negative to positive, a debate might be inevitable in the
process of adapting to the new system.
A considerable amount of effort is required from both the
government and industry to strengthen the transparency of the
system and establish a solid base for evidence-based decision-
making through that process. More active solutions such as the
introduction of a prior-consultation program being reviewed by
HIRA need to be continuously considered. In addition, commu-
nication between the government and stakeholders should take
place more frequently and in more diverse ways. On the inter-
national level, more effort is needed in networking. There may be
differences in prices, medical utilization patterns, or the basic
epidemiology of a population according to the country, but data
on the treatment effects of drugs can be used similarly in many
countries. Sharing the clinical effectiveness-related data accumu-
lated in each country can make evaluations more efﬁcient. In
particular, networking among health technology assessment
(HTA) agencies in the Asia region is important because there are
some similarities in epidemiology and policy contexts in the
region. Recently, Thailand and Taiwan set up units that conduct
health technology assessments to support an insurer or govern-
ment decisions. Signiﬁcant collaboration between HTA agencies
in the region is expected in the future.
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